Industry Research Reports

Home > Reports > Medical Care > Treatment for Communicable Diseases - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Treatment for Communicable Diseases - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 134 Pages

Report ld: 2342038

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites
The global market for Treatment for Communicable Diseases was estimated to be worth US$ 28160 million in 2023 and is forecast to a readjusted size of US$ 68580 million by 2030 with a CAGR of 6.6% during the forecast period 2024-2030

Treatment for Communicable Diseases Market Size

M= millions and B=billions

The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Treatment for Communicable Diseases, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Treatment for Communicable Diseases by region & country, by Type, and by Application.

The Treatment for Communicable Diseases market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Treatment for Communicable Diseases.

Market Segmentation

Report Metric
Details
Report Title
Treatment for Communicable Diseases - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 68580 million
CAGR(2024-2030)
6.6%
Market Size Available for Years
2019-2030
Global Treatment for Communicable Diseases Companies Covered
Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca, J & J, Teva, AbbVie, Bausch Health, Abbott, Sanofi, Sun Pharma, Endo, Apotex, Amneal Pharma, Torrent Pharma
Global Treatment for Communicable Diseases Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Treatment for Communicable Diseases Market, Segment by Type
HIV

Influenza

TB

Malaria

Hepatitis

HPV
Global Treatment for Communicable Diseases Market, Segment by Application
Hospital

Clinic

Other
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Treatment for Communicable Diseases manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Treatment for Communicable Diseases in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Treatment for Communicable Diseases in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

 1 Market Overview
    1.1 Treatment for Communicable Diseases Product Introduction
    1.2 Global Treatment for Communicable Diseases Market Size Forecast
    1.3 Treatment for Communicable Diseases Market Trends & Drivers
        1.3.1 Treatment for Communicable Diseases Industry Trends
        1.3.2 Treatment for Communicable Diseases Market Drivers & Opportunity
        1.3.3 Treatment for Communicable Diseases Market Challenges
        1.3.4 Treatment for Communicable Diseases Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Treatment for Communicable Diseases Players Revenue Ranking (2023)
    2.2 Global Treatment for Communicable Diseases Revenue by Company (2019-2024)
    2.3 Key Companies Treatment for Communicable Diseases Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Treatment for Communicable Diseases Product Offered
    2.5 Key Companies Time to Begin Mass Production of Treatment for Communicable Diseases
    2.6 Treatment for Communicable Diseases Market Competitive Analysis
        2.6.1 Treatment for Communicable Diseases Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Treatment for Communicable Diseases Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treatment for Communicable Diseases as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 HIV
        3.1.2 Influenza
        3.1.3 TB
        3.1.4 Malaria
        3.1.5 Hepatitis
        3.1.6 HPV
    3.2 Global Treatment for Communicable Diseases Sales Value by Type
        3.2.1 Global Treatment for Communicable Diseases Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Treatment for Communicable Diseases Sales Value, by Type (2019-2030)
        3.2.3 Global Treatment for Communicable Diseases Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospital
        4.1.2 Clinic
        4.1.3 Other
    4.2 Global Treatment for Communicable Diseases Sales Value by Application
        4.2.1 Global Treatment for Communicable Diseases Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Treatment for Communicable Diseases Sales Value, by Application (2019-2030)
        4.2.3 Global Treatment for Communicable Diseases Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Treatment for Communicable Diseases Sales Value by Region
        5.1.1 Global Treatment for Communicable Diseases Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Treatment for Communicable Diseases Sales Value by Region (2019-2024)
        5.1.3 Global Treatment for Communicable Diseases Sales Value by Region (2025-2030)
        5.1.4 Global Treatment for Communicable Diseases Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Treatment for Communicable Diseases Sales Value, 2019-2030
        5.2.2 North America Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Treatment for Communicable Diseases Sales Value, 2019-2030
        5.3.2 Europe Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Treatment for Communicable Diseases Sales Value, 2019-2030
        5.4.2 Asia Pacific Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Treatment for Communicable Diseases Sales Value, 2019-2030
        5.5.2 South America Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Treatment for Communicable Diseases Sales Value, 2019-2030
        5.6.2 Middle East & Africa Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Treatment for Communicable Diseases Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Treatment for Communicable Diseases Sales Value
    6.3 United States
        6.3.1 United States Treatment for Communicable Diseases Sales Value, 2019-2030
        6.3.2 United States Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Treatment for Communicable Diseases Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Treatment for Communicable Diseases Sales Value, 2019-2030
        6.4.2 Europe Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Treatment for Communicable Diseases Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Treatment for Communicable Diseases Sales Value, 2019-2030
        6.5.2 China Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Treatment for Communicable Diseases Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Treatment for Communicable Diseases Sales Value, 2019-2030
        6.6.2 Japan Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Treatment for Communicable Diseases Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Treatment for Communicable Diseases Sales Value, 2019-2030
        6.7.2 South Korea Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Treatment for Communicable Diseases Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Treatment for Communicable Diseases Sales Value, 2019-2030
        6.8.2 Southeast Asia Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Treatment for Communicable Diseases Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Treatment for Communicable Diseases Sales Value, 2019-2030
        6.9.2 India Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Treatment for Communicable Diseases Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Novartis
        7.1.1 Novartis Profile
        7.1.2 Novartis Main Business
        7.1.3 Novartis Treatment for Communicable Diseases Products, Services and Solutions
        7.1.4 Novartis Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.1.5 Novartis Recent Developments
    7.2 Gilead
        7.2.1 Gilead Profile
        7.2.2 Gilead Main Business
        7.2.3 Gilead Treatment for Communicable Diseases Products, Services and Solutions
        7.2.4 Gilead Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.2.5 Gilead Recent Developments
    7.3 GSK
        7.3.1 GSK Profile
        7.3.2 GSK Main Business
        7.3.3 GSK Treatment for Communicable Diseases Products, Services and Solutions
        7.3.4 GSK Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.3.5 Roche Recent Developments
    7.4 Roche
        7.4.1 Roche Profile
        7.4.2 Roche Main Business
        7.4.3 Roche Treatment for Communicable Diseases Products, Services and Solutions
        7.4.4 Roche Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.4.5 Roche Recent Developments
    7.5 Merck
        7.5.1 Merck Profile
        7.5.2 Merck Main Business
        7.5.3 Merck Treatment for Communicable Diseases Products, Services and Solutions
        7.5.4 Merck Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.5.5 Merck Recent Developments
    7.6 Boehringer Ingelheim
        7.6.1 Boehringer Ingelheim Profile
        7.6.2 Boehringer Ingelheim Main Business
        7.6.3 Boehringer Ingelheim Treatment for Communicable Diseases Products, Services and Solutions
        7.6.4 Boehringer Ingelheim Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.6.5 Boehringer Ingelheim Recent Developments
    7.7 Eli Lilly
        7.7.1 Eli Lilly Profile
        7.7.2 Eli Lilly Main Business
        7.7.3 Eli Lilly Treatment for Communicable Diseases Products, Services and Solutions
        7.7.4 Eli Lilly Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.7.5 Eli Lilly Recent Developments
    7.8 AstraZeneca
        7.8.1 AstraZeneca Profile
        7.8.2 AstraZeneca Main Business
        7.8.3 AstraZeneca Treatment for Communicable Diseases Products, Services and Solutions
        7.8.4 AstraZeneca Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.8.5 AstraZeneca Recent Developments
    7.9 J & J
        7.9.1 J & J Profile
        7.9.2 J & J Main Business
        7.9.3 J & J Treatment for Communicable Diseases Products, Services and Solutions
        7.9.4 J & J Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.9.5 J & J Recent Developments
    7.10 Teva
        7.10.1 Teva Profile
        7.10.2 Teva Main Business
        7.10.3 Teva Treatment for Communicable Diseases Products, Services and Solutions
        7.10.4 Teva Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.10.5 Teva Recent Developments
    7.11 AbbVie
        7.11.1 AbbVie Profile
        7.11.2 AbbVie Main Business
        7.11.3 AbbVie Treatment for Communicable Diseases Products, Services and Solutions
        7.11.4 AbbVie Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.11.5 AbbVie Recent Developments
    7.12 Bausch Health
        7.12.1 Bausch Health Profile
        7.12.2 Bausch Health Main Business
        7.12.3 Bausch Health Treatment for Communicable Diseases Products, Services and Solutions
        7.12.4 Bausch Health Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.12.5 Bausch Health Recent Developments
    7.13 Abbott
        7.13.1 Abbott Profile
        7.13.2 Abbott Main Business
        7.13.3 Abbott Treatment for Communicable Diseases Products, Services and Solutions
        7.13.4 Abbott Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.13.5 Abbott Recent Developments
    7.14 Sanofi
        7.14.1 Sanofi Profile
        7.14.2 Sanofi Main Business
        7.14.3 Sanofi Treatment for Communicable Diseases Products, Services and Solutions
        7.14.4 Sanofi Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.14.5 Sanofi Recent Developments
    7.15 Sun Pharma
        7.15.1 Sun Pharma Profile
        7.15.2 Sun Pharma Main Business
        7.15.3 Sun Pharma Treatment for Communicable Diseases Products, Services and Solutions
        7.15.4 Sun Pharma Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.15.5 Sun Pharma Recent Developments
    7.16 Endo
        7.16.1 Endo Profile
        7.16.2 Endo Main Business
        7.16.3 Endo Treatment for Communicable Diseases Products, Services and Solutions
        7.16.4 Endo Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.16.5 Endo Recent Developments
    7.17 Apotex
        7.17.1 Apotex Profile
        7.17.2 Apotex Main Business
        7.17.3 Apotex Treatment for Communicable Diseases Products, Services and Solutions
        7.17.4 Apotex Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.17.5 Apotex Recent Developments
    7.18 Amneal Pharma
        7.18.1 Amneal Pharma Profile
        7.18.2 Amneal Pharma Main Business
        7.18.3 Amneal Pharma Treatment for Communicable Diseases Products, Services and Solutions
        7.18.4 Amneal Pharma Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.18.5 Amneal Pharma Recent Developments
    7.19 Torrent Pharma
        7.19.1 Torrent Pharma Profile
        7.19.2 Torrent Pharma Main Business
        7.19.3 Torrent Pharma Treatment for Communicable Diseases Products, Services and Solutions
        7.19.4 Torrent Pharma Treatment for Communicable Diseases Revenue (US$ Million) & (2019-2024)
        7.19.5 Torrent Pharma Recent Developments

 8 Industry Chain Analysis
    8.1 Treatment for Communicable Diseases Industrial Chain
    8.2 Treatment for Communicable Diseases Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Treatment for Communicable Diseases Sales Model
        8.5.2 Sales Channel
        8.5.3 Treatment for Communicable Diseases Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Treatment for Communicable Diseases Market Trends
    Table 2. Treatment for Communicable Diseases Market Drivers & Opportunity
    Table 3. Treatment for Communicable Diseases Market Challenges
    Table 4. Treatment for Communicable Diseases Market Restraints
    Table 5. Global Treatment for Communicable Diseases Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Treatment for Communicable Diseases Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Treatment for Communicable Diseases Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Treatment for Communicable Diseases Product Type
    Table 9. Key Companies Time to Begin Mass Production of Treatment for Communicable Diseases
    Table 10. Global Treatment for Communicable Diseases Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treatment for Communicable Diseases as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Treatment for Communicable Diseases Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Treatment for Communicable Diseases Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Treatment for Communicable Diseases Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Treatment for Communicable Diseases Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Treatment for Communicable Diseases Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Treatment for Communicable Diseases Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Treatment for Communicable Diseases Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Treatment for Communicable Diseases Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Treatment for Communicable Diseases Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Treatment for Communicable Diseases Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Treatment for Communicable Diseases Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Treatment for Communicable Diseases Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Treatment for Communicable Diseases Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Treatment for Communicable Diseases Sales Value by Region (2019-2024) & (%)
    Table 27. Global Treatment for Communicable Diseases Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Treatment for Communicable Diseases Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Treatment for Communicable Diseases Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Treatment for Communicable Diseases Sales Value, (2025-2030) & (US$ Million)
    Table 31. Novartis Basic Information List
    Table 32. Novartis Description and Business Overview
    Table 33. Novartis Treatment for Communicable Diseases Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Novartis (2019-2024)
    Table 35. Novartis Recent Developments
    Table 36. Gilead Basic Information List
    Table 37. Gilead Description and Business Overview
    Table 38. Gilead Treatment for Communicable Diseases Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Gilead (2019-2024)
    Table 40. Gilead Recent Developments
    Table 41. GSK Basic Information List
    Table 42. GSK Description and Business Overview
    Table 43. GSK Treatment for Communicable Diseases Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Treatment for Communicable Diseases Business of GSK (2019-2024)
    Table 45. GSK Recent Developments
    Table 46. Roche Basic Information List
    Table 47. Roche Description and Business Overview
    Table 48. Roche Treatment for Communicable Diseases Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Roche (2019-2024)
    Table 50. Roche Recent Developments
    Table 51. Merck Basic Information List
    Table 52. Merck Description and Business Overview
    Table 53. Merck Treatment for Communicable Diseases Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Merck (2019-2024)
    Table 55. Merck Recent Developments
    Table 56. Boehringer Ingelheim Basic Information List
    Table 57. Boehringer Ingelheim Description and Business Overview
    Table 58. Boehringer Ingelheim Treatment for Communicable Diseases Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Boehringer Ingelheim (2019-2024)
    Table 60. Boehringer Ingelheim Recent Developments
    Table 61. Eli Lilly Basic Information List
    Table 62. Eli Lilly Description and Business Overview
    Table 63. Eli Lilly Treatment for Communicable Diseases Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Eli Lilly (2019-2024)
    Table 65. Eli Lilly Recent Developments
    Table 66. AstraZeneca Basic Information List
    Table 67. AstraZeneca Description and Business Overview
    Table 68. AstraZeneca Treatment for Communicable Diseases Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Treatment for Communicable Diseases Business of AstraZeneca (2019-2024)
    Table 70. AstraZeneca Recent Developments
    Table 71. J & J Basic Information List
    Table 72. J & J Description and Business Overview
    Table 73. J & J Treatment for Communicable Diseases Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Treatment for Communicable Diseases Business of J & J (2019-2024)
    Table 75. J & J Recent Developments
    Table 76. Teva Basic Information List
    Table 77. Teva Description and Business Overview
    Table 78. Teva Treatment for Communicable Diseases Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Teva (2019-2024)
    Table 80. Teva Recent Developments
    Table 81. AbbVie Basic Information List
    Table 82. AbbVie Description and Business Overview
    Table 83. AbbVie Treatment for Communicable Diseases Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Treatment for Communicable Diseases Business of AbbVie (2019-2024)
    Table 85. AbbVie Recent Developments
    Table 86. Bausch Health Basic Information List
    Table 87. Bausch Health Description and Business Overview
    Table 88. Bausch Health Treatment for Communicable Diseases Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Bausch Health (2019-2024)
    Table 90. Bausch Health Recent Developments
    Table 91. Abbott Basic Information List
    Table 92. Abbott Description and Business Overview
    Table 93. Abbott Treatment for Communicable Diseases Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Abbott (2019-2024)
    Table 95. Abbott Recent Developments
    Table 96. Sanofi Basic Information List
    Table 97. Sanofi Description and Business Overview
    Table 98. Sanofi Treatment for Communicable Diseases Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Sanofi (2019-2024)
    Table 100. Sanofi Recent Developments
    Table 101. Sun Pharma Basic Information List
    Table 102. Sun Pharma Description and Business Overview
    Table 103. Sun Pharma Treatment for Communicable Diseases Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Sun Pharma (2019-2024)
    Table 105. Sun Pharma Recent Developments
    Table 106. Endo Basic Information List
    Table 107. Endo Description and Business Overview
    Table 108. Endo Treatment for Communicable Diseases Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Endo (2019-2024)
    Table 110. Endo Recent Developments
    Table 111. Apotex Basic Information List
    Table 112. Apotex Description and Business Overview
    Table 113. Apotex Treatment for Communicable Diseases Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Apotex (2019-2024)
    Table 115. Apotex Recent Developments
    Table 116. Amneal Pharma Basic Information List
    Table 117. Amneal Pharma Description and Business Overview
    Table 118. Amneal Pharma Treatment for Communicable Diseases Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Amneal Pharma (2019-2024)
    Table 120. Amneal Pharma Recent Developments
    Table 121. Torrent Pharma Basic Information List
    Table 122. Torrent Pharma Description and Business Overview
    Table 123. Torrent Pharma Treatment for Communicable Diseases Products, Services and Solutions
    Table 124. Revenue (US$ Million) in Treatment for Communicable Diseases Business of Torrent Pharma (2019-2024)
    Table 125. Torrent Pharma Recent Developments
    Table 126. Key Raw Materials Lists
    Table 127. Raw Materials Key Suppliers Lists
    Table 128. Treatment for Communicable Diseases Downstream Customers
    Table 129. Treatment for Communicable Diseases Distributors List
    Table 130. Research Programs/Design for This Report
    Table 131. Key Data Information from Secondary Sources
    Table 132. Key Data Information from Primary Sources
    Table 133. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Treatment for Communicable Diseases Product Picture
    Figure 2. Global Treatment for Communicable Diseases Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Treatment for Communicable Diseases Sales Value (2019-2030) & (US$ Million)
    Figure 4. Treatment for Communicable Diseases Report Years Considered
    Figure 5. Global Treatment for Communicable Diseases Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Treatment for Communicable Diseases Revenue in 2023
    Figure 7. Treatment for Communicable Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. HIV Picture
    Figure 9. Influenza Picture
    Figure 10. TB Picture
    Figure 11. Malaria Picture
    Figure 12. Hepatitis Picture
    Figure 13. HPV Picture
    Figure 14. Global Treatment for Communicable Diseases Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Treatment for Communicable Diseases Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Product Picture of Hospital
    Figure 17. Product Picture of Clinic
    Figure 18. Product Picture of Other
    Figure 19. Global Treatment for Communicable Diseases Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 20. Global Treatment for Communicable Diseases Sales Value Market Share by Application, 2023 & 2030
    Figure 21. North America Treatment for Communicable Diseases Sales Value (2019-2030) & (US$ Million)
    Figure 22. North America Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030
    Figure 23. Europe Treatment for Communicable Diseases Sales Value (2019-2030) & (US$ Million)
    Figure 24. Europe Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030
    Figure 25. Asia Pacific Treatment for Communicable Diseases Sales Value (2019-2030) & (US$ Million)
    Figure 26. Asia Pacific Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030
    Figure 27. South America Treatment for Communicable Diseases Sales Value (2019-2030) & (US$ Million)
    Figure 28. South America Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030
    Figure 29. Middle East & Africa Treatment for Communicable Diseases Sales Value (2019-2030) & (US$ Million)
    Figure 30. Middle East & Africa Treatment for Communicable Diseases Sales Value by Country (%), 2023 VS 2030
    Figure 31. Key Countries/Regions Treatment for Communicable Diseases Sales Value (%), (2019-2030)
    Figure 32. United States Treatment for Communicable Diseases Sales Value, (2019-2030) & (US$ Million)
    Figure 33. United States Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
    Figure 34. United States Treatment for Communicable Diseases Sales Value by Application (%), 2023 VS 2030
    Figure 35. Europe Treatment for Communicable Diseases Sales Value, (2019-2030) & (US$ Million)
    Figure 36. Europe Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
    Figure 37. Europe Treatment for Communicable Diseases Sales Value by Application (%), 2023 VS 2030
    Figure 38. China Treatment for Communicable Diseases Sales Value, (2019-2030) & (US$ Million)
    Figure 39. China Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
    Figure 40. China Treatment for Communicable Diseases Sales Value by Application (%), 2023 VS 2030
    Figure 41. Japan Treatment for Communicable Diseases Sales Value, (2019-2030) & (US$ Million)
    Figure 42. Japan Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
    Figure 43. Japan Treatment for Communicable Diseases Sales Value by Application (%), 2023 VS 2030
    Figure 44. South Korea Treatment for Communicable Diseases Sales Value, (2019-2030) & (US$ Million)
    Figure 45. South Korea Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
    Figure 46. South Korea Treatment for Communicable Diseases Sales Value by Application (%), 2023 VS 2030
    Figure 47. Southeast Asia Treatment for Communicable Diseases Sales Value, (2019-2030) & (US$ Million)
    Figure 48. Southeast Asia Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
    Figure 49. Southeast Asia Treatment for Communicable Diseases Sales Value by Application (%), 2023 VS 2030
    Figure 50. India Treatment for Communicable Diseases Sales Value, (2019-2030) & (US$ Million)
    Figure 51. India Treatment for Communicable Diseases Sales Value by Type (%), 2023 VS 2030
    Figure 52. India Treatment for Communicable Diseases Sales Value by Application (%), 2023 VS 2030
    Figure 53. Treatment for Communicable Diseases Industrial Chain
    Figure 54. Treatment for Communicable Diseases Manufacturing Cost Structure
    Figure 55. Channels of Distribution (Direct Sales, and Distribution)
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation

In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites
The global market for Treatment for Communicable Diseases was estimated to be worth US$ 28160 million in 2023 and is forecast to a readjusted size of US$ 68580 million by 2030 with a CAGR of 6.6% during the forecast period 2024-2030

Market Segmentation

Industry: Medical Care

Published: 2024-01-24

Pages: 134 Pages

Report ld: 2342038

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 3950.00

Multi Users License

USD 5925.00